9.9
CiteScore
7.1
Impact Factor
Turn off MathJax
Article Contents
Article Navigation >  Journal of Genetics and Genomics  > 2026  > Accepted Manuscript

Gene-targeted versus broad-spectrum therapies in ALS: comparative lessons and strategic outlook

doi: 10.1016/j.jgg.2026.01.012
  •  

    a. School of Life Science and Technology & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai 201210, China;

  •  

    b. Shanghai Alliance Investment LTD, Shanghai 200031, China;

  •  

    c. Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu 226019, China;

  •  

    d. Shanghai Clinical Research and Trial Center, Shanghai 201210, China

Funds:

This work was partially supported by the National Key Research and Development Program of China (2024YFA1108000, 2021ZD0202500), the National Natural Science Foundation of China (32130035), The Joint Project of the Yangtze River Delta Science and Technology Innovation Community (2024CSJZN0600), Changping Laboratory (2025B-07-15), and Lingang Labarotary (LGL-8998-11).

  • Received Date: 2025-10-30
  • Accepted Date: 2026-01-30
  • Rev Recd Date: 2026-01-19
    • Available Online: 2026-02-09
    Abstract
    • FullText(HTML)
  • loading
    • References(241)
  • AB Science. 2025a. AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting–AB Science. https://www.ab-science.com/ab-science-will-present-new-data-from-masitinib-clinical-program-in-als-in-two-presentations-at-the-2025-encals-annual-meeting/ (accessed January 12, 2026)
    AB Science. 2025b. Summary of the webcast held on January 28, 2025–AB Science. https://www.ab-science.com/summary-of-the-webcast-held-on-january-28-2025/ (accessed January 11, 2026)
    Abe, K., Aoki, M., Tsuji, S., Itoyama, Y., Sobue, G., Togo, M., Hamada, C., Tanaka, M., Akimoto, M., Nakamura, K., et al., 2017. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 16, 505-512.
    Abe, K., Itoyama, Y., Sobue, G., Tsuji, S., Aoki, M., Doyu, M., Hamada, C., Kondo, K., Yoneoka, T., Akimoto, M., et al., 2014. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph. Lateral Scler. Frontotemporal Degener. 15, 610.
    Abe, K., Itoyama, Y., Tsuji, S., Sobue, G., Aoki, M., Doyu, M., Hamada, C., Sasaki, H., Takei, A., Yamashita, I., et al., 2017. Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 18, 20-31.
    Abel, O., Powell, JF., Andersen, PM., Al-Chalabi, A. 2012. ALSoD: a user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum. Mutat. 33, 1345-1351.
    Abu-Rumeileh, S., Vacchiano, V., Zenesini, C., Polischi, B., de Pasqua, S., Fileccia, E., Mammana, A., Di Stasi, V., Capellari, S., Salvi, F., et al., 2020. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. J. Neurol. 267, 1699-1708.
    Akcimen, F., Lopez, ER., Landers, JE., Nath, A., Chio, A., Chia, R., Traynor, BJ. 2023. Amyotrophic lateral sclerosis: translating genetic discoveries into therapies. Nat. Rev. Genet. 24, 642-658.
    Amylyx Pharmaceuticals. 2022. Amylyx pharmaceuticals announces FDA approval of RELYVRIOTM for the treatment of ALS | Amylyx. https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-fda-approval-of-relyvriotm-for-the-treatment-of-als (accessed December 16, 2025)
    Amylyx Pharmaceuticals. 2024. Amylyx pharmaceuticals announces formal intention to remove RELYVRIO®/ALBRIOZATM from the market; provides updates on access to therapy, pipeline, corporate restructuring, and strategy | Amylyx. https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-formal-intention-to-remove-relyvrior/albriozatm-from-the-market-provides-updates-on-access-to-therapy-pipeline-corporate-restructuring-and-strategy (accessed January 12, 2026)
    Andrews, JA., Jackson, CE., Heiman-Patterson, TD., Bettica, P., Brooks, BR., Pioro, EP. 2020. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 21, 509-518.
    Anjum, F., Bakhuraysah, M., Alsharif, A., Mohammad, T., Shamsi, A., Hassan MI. 2025. Emerging biomarkers in amyotrophic lateral sclerosis: from pathogenesis to clinical applications. Front. Mol. Biosci. 12, 1608853.
    Aoki, M., Warita, H., Mizuno, H., Suzuki, N., Yuki, S., Itoyama Y. 2011. Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger. Brain Res. 1382, 321-325.
    Arnold, C. 2019. Tailored treatment for ALS poised to move ahead. Nat. Med. doi: 10.1038/d41591-019-00013-w.
    Ash, PEA., Bieniek, KF., Gendron, TF., Caulfield, T., Lin, WL., DeJesus-Hernandez, M., Blitterswijk, MM Van., Jansen-West, K., Paul, JW., Rademakers, R., et al., 2013. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77, 639-646.
    Assoni, AF., Foijer, F., Zatz, M. 2022. Amyotrophic lateral sclerosis, FUS and protein synthesis defects. Stem Cell Rev. Rep. 2022 19:3. 19, 625-638.
    Balendra, R., Isaacs, AM. 2018. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat. Rev. Neurol. 14, 544-558.
    Baron, DM., Fenton, AR., Saez-Atienzar, S., Giampetruzzi, A., Sreeram, A., Shankaracharya, Keagle, PJ., Doocy, VR., Smith, NJ., Danielson, EW., et al., 2022. ALS-associated KIF5A mutations abolish autoinhibition resulting in a toxic gain of function. Cell Rep. 39, 110598.
    Becker, LA., Huang, B., Bieri, G., Ma, R., Knowles, DA., Jafar-Nejad, P., Messing, J., Kim, HJ., Soriano, A., Auburger, G., et al., 2017. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544, 367-371.
    Beers DR., Zhao, W., Wang, J., Zhang, X., Wen, S., Neal, D., Thonhoff JR., Alsuliman AS., Shpall, EJ., Rezvani, K., et al., 2017. ALS patients’ regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight 2, e89530.
    Benatar, M., Wuu, J., Andersen, PM., Bucelli, RC., Andrews, JA., Otto, M., Farahany, NA., Harrington, EA., Chen, W., Mitchell, AA., et al., 2022. Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study. Neurotherapeutics 19, 1248-1258.
    Bensimon, G., Lacomblez, L., Delumeau, JC., Bejuit, R., Truffinet, P., Meininger, V. 2002. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J. Neurol. 249, 609-615.
    Bensimon, G., Lacomblez, L., Meininger, V. 1994. A controlled trial of riluzole in amyotrophic lateral sclerosis. N. Engl. J. Med. 330, 585-591.
    Benson, BC., Shaw, PJ., Azzouz, M., Highley, JR, Hautbergue, GM. 2021. Proteinopathies as hallmarks of impaired gene expression, proteostasis and mitochondrial function in amyotrophic lateral sclerosis. Front. Neurosci. 15, 783624.
    Berg, LH Van Den. 2024. Results from a global phase 3 trial evaluating an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in amyotrophic lateral sclerosis.
    van den Berg, LH., Rothstein, JD., Shaw, PJ., Babu, S., Benatar, M., Bucelli, RC., Genge, A., Glass, JD., Hardiman, O., Libri, V., et al., 2024. Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study. Lancet Neurol. 23, 901-912.
    Bernardo, ME., Fibbe, WE. 2013. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 13, 392-402.
    Berry, JD., Cudkowicz, ME., Windebank, AJ., Staff, NP., Owegi, M., Nicholson, K., McKenna-Yasek, D., Levy, YS., Abramov, N., Kaspi, H., et al., 2019. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results. Neurol. 93, e2294.
    Berry, JD., Hagan, M., Zhang, J., Liu, Y., Ciepielewska, M. 2025. Longer disease progression milestone-free time in people with amyotrophic lateral sclerosis treated versus not treated with intravenous edaravone: results from an administrative claims analysis. J. Comp. Eff. Res. 14, e240007.
    Besnard-Guerin, C. 2020. Cytoplasmic localization of amyotrophic lateral sclerosis-related TDP-43 proteins modulates stress granule formation. Eur. J. Neurosci. 52, 3995-4008.
    Biogen. 2024. Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis | Biogen. https://investors.biogen.com/news-releases/news-release-details/biogen-and-ionis-announce-topline-phase-12-study-results (accessed December 18, 2025)
    Boeynaems, S., Bogaert, E., Kovacs, D., Konijnenberg, A., Timmerman, E., Volkov, A., Guharoy, M., Decker, M De, Jaspers, T., Ryan VH., et al., 2017. Phase separation of C9orf72 dipeptide repeats perturbs stress granule dynamics. Mol. Cell. 65, 1044-1055.
    Brooks, BR., Berry, JD., Ciepielewska, M., Liu, Y., Zambrano, GS., Zhang, J., Hagan, M. 2022b. Intravenous edaravone treatment in ALS and survival: an exploratory, retrospective, administrative claims analysis. EClinicalMedicine. 52, 101590.
    Brooks, BR., Heiman-Patterson, T., Wiedau-Pazos, M., Liu, S., Zhang, J., Apple, S. 2022a. Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]. PLoS One 17, e0258614.
    Brooks, BR., Miller, RG., Swash, M., Munsat, TL. 2000. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1, 293-299.
    Brown, AL., Wilkins, OG., Keuss, MJ., Hill, SE., Zanovello, M., Lee, WC., Bampton, A., Lee FCY., Masino, L., Qi, YA., et al., 2022. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature 603, 131-137.
    Brown, CA., Lally, C., Kupelian, V., Flanders, WD. 2021. Estimated prevalence and incidence of amyotrophic lateral sclerosis and SOD1 and C9orf72 genetic variants. Neuroepidemiology 55, 342-353.
    Cabras, S., Manera, U., Di Pede, F., Zocco, G., Vasta, R., Novara, A., Minerva, E., Matteoni, E., De Mattei, F., Pellegrino, G., et al., 2025. Role of 2-[18F]FDG-PET as a biomarker of upper motor neuron involvement in amyotrophic lateral sclerosis. J. Neurol. 272, 766.
    Calvo, A., Moglia, C., Lunetta, C., Marinou, K., Ticozzi, N., Ferrante, GD., Scialo, C., Soraru, G., Trojsi, F., Conte, A., et al., 2017. Factors predicting survival in ALS: a multicenter Italian study. J. Neurol. 264, 54-63.
    Campagnoli, C., Roberts, IAG., Kumar, S., Bennett, PR., Bellantuono, I., Fisk, NM. 2001. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 98, 2396-2402.
    Canosa, A., Martino, A., Giuliani, A., Moglia, C., Vasta, R., Grassano, M., Palumbo, F., Cabras, S., Di Pede, F., De Mattei, F., et al., 2022. Brain metabolic differences between pure bulbar and pure spinal ALS: a 2-[18F]FDG-PET study. J. Neurol. 270, 953.
    Caplan, AI., Dennis, JE. 2006. Mesenchymal stem cells as trophic mediators. J. Cell. Biochem. 98(5), 1076-1084.
    Card, NS., Wairagkar, M., Iacobacci, C., Hou, X., Singer-Clark, T., Willett, FR., Kunz, EM., Fan, C., Nia, MV., Deo, DR., et al., 2024. An accurate and rapidly calibrating speech neuroprosthesis. N. Engl. J. Med. 391, 609-618.
    Cedarbaum, JM., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., Nakanishi, A. 1999. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J. Neurol. Sci. 169, 13-21.
    Cha, SJ., Kim, K. 2022. Effects of the edaravone, a drug approved for the treatment of amyotrophic lateral sclerosis, on mitochondrial function and neuroprotection. Antioxidants 11, 195.
    Chen, L., Liu, X., Tang, L., Zhang, N., Fan, D. 2016. Long-term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients: A real-world cohort study in China. Front. Aging Neurosci. 8, 246.
    Chew, J., Gendron, TF., Prudencio, M., Sasaguri, H., Zhang, YJ., Castanedes-Casey, M., Lee CW., Jansen-West, K., Kurti, A., Murray, ME., et al., 2015. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science 348, 1151.
    Chio, A., Calvo, A., Moglia, C., Mazzini, L., Mora, G., Mutani, R., Balma, M., Cammarosano, S., Canosa, A., Gallo, S., et al., 2011. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J. Neurol. Neurosurg. Psychiatry. 82, 740-746.
    Choi, SY., Lopez-Gonzalez, R., Krishnan, G., Phillips, HL., Li, AN., Seeley, WW., Yao, WD., Almeida, S., Gao, FB. 2019. C9ORF72-ALS/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo. Nat. Neurosci. 22, 851-862.
    Colombrita, C., Zennaro, E., Fallini, C., Weber, M., Sommacal, A., Buratti, E., Silani, V., Ratti A. 2009. TDP-43 is recruited to stress granules in conditions of oxidative insult. J. Neurochem. 111, 1051-1061.
    Conte, A., Lattante, S., Zollino, M., Marangi, G., Luigetti, M., Grande, A Del, Servidei, S., Trombetta, F., Sabatelli, M. 2012. P525L FUS mutation is consistently associated with a severe form of juvenile Amyotrophic Lateral Sclerosis. Neuromuscul. Disord. 22, 73-75.
    Corestemchemon. 2025. News | PR | corestemchemon Stemcell Celltherapy. https://www.corestemchemon.com/eng/pr/media.html?bmain=view&uid=119&search=%26page%3D1 (accessed January 10, 2026)
    Crooke, ST. 1999. Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta-Gene Struct. Expression. 1489, 31-43.
    Cudkowicz, ME., Lindborg, SR., Goyal, NA., Miller, RG., Burford, MJ., Berry, JD., Nicholson KA., Mozaffar, T., Katz, JS., Jenkins, LJ., et al., 2022. A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle Nerve 65, 291.
    Damme, P Van, Bogaert, E., Dewil, M., Hersmus, N., Kiraly, D., Scheveneels, W., Bockx, I., Braeken, D., Verpoorten, N., Verhoeven, K., et al., 2007. Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proc. Natl. Acad. Sci. U. S. A. 104, 14825.
    DeJesus-Hernandez, M., Mackenzie, IR., Boeve, BF., Boxer, AL., Baker, M., Rutherford, NJ., Nicholson, AM., Finch, NCA., Flynn, H., Adamson, J., et al., 2011. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245-256.
    Dionisio, PA., Amaral, JD., Ribeiro, MF., Lo, AC., D’Hooge, R., Rodrigues, CMP. 2015. Amyloid-β pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset. Neurobiol. Aging 36, 228-240.
    Dormann, D., Rodde, R., Edbauer, D., Bentmann, E., Fischer, I., Hruscha, A., Than, ME., MacKenzie, IRA., Capell, A., Schmid, B., et al., 2010. ALS-associated fused in sarcoma (FUS) mutations disrupt transportin-mediated nuclear import. EMBO J. 29, 2841-2857.
    Dudman, J., Qi, X. 2020. Stress Granule Dysregulation in Amyotrophic Lateral Sclerosis. Front. Cell. Neurosci. 14, 598517.
    Dyer, MS., Reale, LA., Lewis, KE., Walker, AK., Dickson, TC., Woodhouse, A., Blizzard, CA. 2021. Mislocalisation of TDP-43 to the cytoplasm causes cortical hyperexcitability and reduced excitatory neurotransmission in the motor cortex. J. Neurochem. 157, 1300-1315.
    Elden, AC., Kim HJ., Hart, MP., Chen-Plotkin, AS., Johnson, BS., Fang, X., Armakola, M., Geser, F., Greene, R., Lu, MM., et al., 2010. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069-1075.
    Everett, WH., Bucelli, RC. 2024. Tofersen for SOD1 ALS. Neurodegener. Dis. Manag. 14, 149.
    Falconer, DS. 1956. Wobbler (wr). Mouse News Lett. 15.
    Fang, T., Khleifat A Al, Meurgey JH., Jones, A., Leigh PN., Bensimon, G., Al-Chalabi A. 2018. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 17, 416.
    Favero, FM., Voos, MC., Castro, I De, Caromano, FA., Oliveira, ASB. 2017. Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS. Arq. Neuropsiquiatr. 75, 515-522.
    FDA. 2022. FDA Approves Oral Form for the treatment of adults with amyotrophic lateral sclerosis (ALS) | FDA. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-oral-form-treatment-adults-amyotrophic-lateral-sclerosis-als (accessed December 16, 2026)
    FDA. 2023. FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene | FDA. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene (accessed December 16, 2026)
    Ferrer. 2024. Ferrer reports top-line results from Phase III ADORE study in ALS | Ferrer. https://www.ferrer.com/en/results-study-ADORE-ALS (accessed December 16, 2025)
    Folch, J., Petrov, D., Ettcheto, M., Pedros, I., Abad, S., Beas-Zarate, C., Lazarowski, A., Marin, M., Olloquequi, J., Auladell, C., Camins, A. 2015. Masitinib for the treatment of mild to moderate Alzheimer’s disease. Expert Rev. Neurother. 15, 587-596.
    Forrest, BD., Goyal, NA., Fleming, TR., Bracci, PM., Brett, NR., Khan, Z., Robinson, M., Azhir, A., McGrath, M. 2024. The effectiveness of NP001 on the long-term survival of patients with amyotrophic lateral sclerosis. Biomedicines 12, 2367.
    Freischmidt, A., Wieland, T., Richter, B., Ruf, W., Schaeffer, V., Muller, K., Marroquin, N., Nordin, F., Hubers, A., Weydt, P., et al., 2015. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 18, 631-636.
    Gaiottino, J., Norgren, N., Dobson, R., Topping, J., Nissim, A., Malaspina, A., Bestwick, JP., Monsch, AU., Regeniter, A., Lindberg, RL., et al., 2013. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One 8, e75091.
    Georgoulopoulou, E., Fini, N., Vinceti, M., Monelli, M., Vacondio, P., Bianconi, G., Sola, P., Nichelli, P., Mandrioli J. 2013. The impact of clinical factors, riluzole and therapeutic interventions on ALS survival: A population based study in Modena, Italy. Amyotroph. Lateral Scler. Frontotemporal Degener. 14, 338-345.
    Gille, B., De Schaepdryver, M., Goossens, J., Dedeene, L., De Vocht, J., Oldoni, E., Goris, A., Van Den Bosch, L., Depreitere, B., Claeys, KG., et al., 2019. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis. Neuropathol. Appl. Neurobiol. 45, 291-304.
    Giorgio, FP Di, Carrasco, MA., Siao, MC., Maniatis, T., Eggan, K. 2007. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat. Neurosci. 10, 608.
    Glass, JD., Dewan, R., Ding, J., Gibbs, JR., Dalgard, C., Keagle, PJ., Shankaracharya, Garcia-Redondo, A., Traynor, BJ., Chia, R., Landers, JE. 2022. ATXN2 intermediate expansions in amyotrophic lateral sclerosis. Brain. 145, 2671-2676.
    Goodman, LD., Bonini, NM. 2019. Repeat-associated non-AUG (RAN) translation mechanisms running into focus for GGGGCC-repeat associated ALS/FTD. Prog. Neurobiol. 183, 101697.
    Gothelf, Y., Abramov, N., Harel, A., Offen, D. 2014. Safety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cells. Clin. Transl. Med. 3, 21.
    Gothelf, Y., Kaspi, H., Abramov, N., Aricha, R. 2017. miRNA profiling of NurOwn®: mesenchymal stem cells secreting neurotrophic factors. Stem Cell Res. Ther. 8, 249.
    Gotkine, M., Caraco, Y., Lerner, Y., Blotnick, S., Wanounou, M., Slutsky, SG., Chebath, J., Kuperstein, G., Estrin, E., Ben-Hur, T., et al., 2023. Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx®) in ALS patients: phase I/IIa clinical trial results. J. Transl. Med. 21, 122.
    Goutman, SA., Hardiman, O., Al-Chalabi, A., Chio, A., Savelieff, MG., Kiernan, MC., Feldman, EL. 2022. Emerging insights into the complex genetics and pathophysiology of ALS. Lancet Neurol. 21, 465.
    Gregorczyk, M., Pastore, G., Munoz, I., Carroll, T., Streubel, J., Munro, M., Lis, P., Lange, S., Lamoliatte, F., Macartney, T., et al., 2023. Functional characterization of C21ORF2 association with the NEK1 kinase mutated in human in diseases. Life Sci. Alliance. 6, e202201740.
    Gurney, ME., Pu, H., Chiu, AY., Dal Canto, MC., Polchow, CY., Alexander, DD., Caliendo, J., Hentati, A., Kwon, YW., Deng, HX., et al., 1994. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264, 1772-1775.
    Hahn KA., Oglivie, G., Rusk, T., Devauchelle, P., Leblanc, A., Legendre, A., Powers, B., Leventhal, PS., Kinet, JP., Palmerini, F., et al., 2008. Masitinib is safe and effective for the treatment of canine mast cell tumors. J. Vet. Intern. Med. 22, 1301-1309.
    Haidet-Phillips, AM., Hester, ME., Miranda, CJ., Meyer, K., Braun, L., Frakes, A., Song, S., Likhite, S., Murtha, MJ., Foust, KD., et al., 2011. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 29, 824.
    Hardiman, O., Al-Chalabi, A., Chio, A., Corr, EM., Logroscino, G., Robberecht, W., Shaw, PJ., Simmons, Z., Berg, LH Van Den. 2017. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers 3, 1-19.
    Harris, F., Berdugo YA., Tree T. 2022. IL-2-based approaches to Treg enhancement. Clin. Exp. Immunol. 211, 149.
    Hayashi, Y., Homma, K., Ichijo H. 2016. SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS. Adv. Biol. Regul. 60, 95-104.
    He, J., Fan, D. 2025. Amyotrophic lateral sclerosis in Mainland China: clinical translational challenges and opportunities. Curr. Opin. Neurol. 38, 596.
    Herranz-Martin, S., Chandran, J., Lewis, K., Mulcahy, P., Higginbottom, A., Walker, C., Valenzuela, IMPY., Jones, RA., Coldicott, I., Iannitti, T., et al., 2017. Viral delivery of C9orf72 hexanucleotide repeat expansions in mice leads to repeat-length-dependent neuropathology and behavioural deficits. Dis. Model. Mech. 10, 859.
    Hinchcliffe, M., Smith, A. 2017. Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degener. Neurol. Neuromuscul. Dis. 7, 61.
    Hooten, KG., Beers, DR., Zhao, W., Appel, SH. 2015. Protective and toxic neuroinflammation in amyotrophic lateral sclerosis. Neurotherapeutics 12, 364-375.
    Hung, S., Cheng, H., Pan, C., Tsai, MJ., Kao, L., Ma, H. 2002. In vitro differentiation of size-sieved stem cells into electrically active neural cells. Stem Cells 20, 522-529.
    Ikeda, K., Iwasaki, Y. 2015. Edaravone, a free radical scavenger, delayed symptomatic and pathological progression of motor neuron disease in the wobbler mouse. PLoS One 10, e0140316.
    Im, G Il, Shin, YW., Lee, KB. 2005. Do adipose tissue-derived mesenchymal stem cells have the same osteogenic and chondrogenic potential as bone marrow-derived cells? Osteoarthritis Cartilage. 13, 845-853.
    Ito, Hidefumi., Wate, R., Zhang, J., Ohnishi, S., Kaneko, S., Ito, Hisashi., Nakano, S., Kusaka, H. 2008. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp. Neurol. 213, 448-455.
    Izrael, M., Slutsky, SG., Admoni, T., Cohen, L., Granit, A., Hasson, A., Itskovitz-Eldor, J., Paker, LK., Kuperstein, G., Lavon, N., et al., 2018. Safety and efficacy of human embryonic stem cell-derived astrocytes following intrathecal transplantation in SOD1G93A and NSG animal models. Stem Cell Res. Ther. 9, 152.
    Javorkova, E., Matejckova, N., Zajicova, A., Hermankova, B., Hajkova, M., Bohacova, P., Kossl, J., Krulova, M., Holan, V. 2019. Immunomodulatory properties of bone marrow mesenchymal stem cells from patients with amyotrophic lateral sclerosis and healthy donors. J. Neuroimmune Pharmacol. 14, 215-225.
    Jiang, JS., Li, XG., Mi, YX., Wang, YY., Heng, YX., Li, ZW., Deng, M. 2025. Real-world evidence of riluzole on survival and ALSFRS change in a Chinese ALS cohort. Neurodegener. Dis. Manag. 15, 77-87.
    Jiao, L., Yang, J., Wang, W., Liu, X., Fu, Y., Fan, D. 2024. sTREM2 cerebrospinal fluid levels are a potential biomarker in amyotrophic lateral sclerosis and associate with UMN burden. Front. Neurol. 15, 1515252.
    Jin, J., Hu, F., Zhang, Q., Jia, R., Dang, J. 2016. Hyperintensity of the corticospinal tract on FLAIR: A simple and sensitive objective upper motor neuron degeneration marker in clinically verified amyotrophic lateral sclerosis. J. Neurol. Sci. 367, 177-183.
    Kaur, B., Bhat, A., Chakraborty, R., Adlakha, K., Sengupta, S., Roy, S., Chakraborty, K. 2018. Proteomic profile of 4-PBA treated human neuronal cells during ER stress. Mol. Omics. 14, 53-63.
    Kawashima, N. 2012. Characterisation of dental pulp stem cells: A new horizon for tissue regeneration? Arch. Oral Biol. 57, 1439-1458.
    Kenna, KP., Van Doormaal, PTC., Dekker, AM., Ticozzi, N., Kenna, BJ., Diekstra, FP., Van Rheenen, W., Van Eijk, KR., Jones, AR., Keagle, P., et al., 2016. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat. Genet. 48, 1037-1042.
    Ketabforoush, AHME., Chegini, R., Barati, S., Tahmasebi, F., Moghisseh, B., Joghataei, MT., Faghihi, F., Azedi, F. 2023. Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series. Biomed. Pharmacother. 160, 114378.
    Khalil, M., Teunissen, CE., Lehmann, S., Otto, M., Piehl, F., Ziemssen, T., Bittner, S., Sormani, MP., Gattringer, T., Abu-Rumeileh, S., et al., 2024. Neurofilaments as biomarkers in neurological disorders - towards clinical application. Nat. Rev. Neurol. 20, 269-287.
    Kim, H., Kim, HY., Choi, MR., Hwang, S., Nam, KH., Kim, HC., Han, JS., Kim, KS., Yoon, HS., Kim, SH. 2010. Dose-dependent efficacy of ALS-human mesenchymal stem cells transplantation into cisterna magna in SOD1-G93A ALS mice. Neurosci. Lett. 468, 190-194.
    Knibb, JA., Keren, N., Kulka, A., Leigh, PN., Martin, S., Shaw, CE., Tsuda, M., Al-Chalabi, A. 2016. A clinical tool for predicting survival in ALS. J. Neurol. Neurosurg. Psychiatry 87, 1361.
    Koh, SH., Noh, MY., Cho, GW., Kim, KS., Kim, SH. 2009. Erythropoietin increases the motility of human bone marrow-multipotent stromal cells (hBM-MSCs) and enhances the production of neurotrophic factors from hBM-MSCs. Stem Cells Dev. 18, 411-421.
    Kondo, T., Funayama, M., Tsukita, K., Hotta, A., Yasuda, A., Nori, S., Kaneko, S., Nakamura, M., Takahashi, R., Okano, H., et al., 2014. Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. Stem Cell Rep. 3, 242.
    Kopalli, SR., Behl, T., Baldaniya, L., Ballal, S., Joshi, KK., Arya, R., Chaturvedi, B., Chauhan AS., Verma, R., Patel, M., et al., 2025. Neuroadaptation in neurodegenerative diseases: compensatory mechanisms and therapeutic approaches. Prog. Neuropsychopharmacol. Biol. Psychiatry. 139, 111375.
    Korobeynikov, VA., Lyashchenko, AK., Blanco-Redondo, B., Jafar-Nejad, P., Shneider, NA. 2022. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat. Med. 28, 104.
    Kusaczuk, M. 2019. Tauroursodeoxycholate-bile acid with chaperoning activity: molecular and cellular effects and therapeutic perspectives. Cells 8, 1471.
    Kwiatkowski, TJ., Bosco, DA., LeClerc, AL., Tamrazian, E., Vanderburg, CR., Russ, C., Davis, A., Gilchrist, J., Kasarskis, EJ., Munsat, T., et al., 2009. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205-1208.
    Kwon, MS., Noh, MY., Oh, KW., Cho, KA., Kang, BY., Kim, KS., Kim, YS., Kim, SH. 2014. The immunomodulatory effects of human mesenchymal stem cells on peripheral blood mononuclear cells in ALS Patients. J. Neurochem. 131, 206-218.
    Lacomblez, L., Bensimon, G., Leigh, PN., Guillet, P., Meininger, V. 1996. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 347, 1425-1431.
    Lattante, S., Rouleau, GA., Kabashi, E. 2013. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum. Mutat. 34, 812-826.
    Lee, CTC., Chiu, YW., Wang, KC., Hwang, CS., Lin, KH., Lee, IT., Tsai, CP. 2013. Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-term survival: a population-based study of 1149 cases in Taiwan. J. Epidemiol. 23, 35.
    Lee, RC., Feinbaum, RL., Ambros, V. 1993. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843-854.
    Lescouzeres, L., Patten, SA. 2024. Promising animal models for amyotrophic lateral sclerosis drug discovery: a comprehensive update. Expert Opin. Drug Discov. 19, 1213-1233.
    Liao, B., Zhao, W., Beers, DR., Henkel, JS., Appel, SH. 2012. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp. Neurol. 237, 147-152.
    Lin TJ., Cheng, GC., Wu, LY., Lai, WY., Ling, TY., Kuo, YC., Huang, YH. 2022. Potential of cellular therapy for ALS: current strategies and future prospects. Front. Cell Dev. Biol. 10, 851613.
    Liu, J., Wang, F. 2017. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front. Immunol. 8, 1005.
    Longinetti, E., Fang, F. 2019. Epidemiology of amyotrophic lateral sclerosis: An update of recent literature. Curr. Opin. Neurol. 32, 771-776.
    Lovett, A., Chary, S., Babu, S., Bruneteau, G., Glass, JD., Karlsborg, M., Ladha, S., Mayl, K., McDermott, C., Bucelli, RC., et al., 2025. Serious neurologic adverse events in Tofersen clinical trials for amyotrophic lateral sclerosis. Muscle Nerve 71, 1006.
    Ludolph, A., Hermine, O. 2023. Masitinib shows prolonged survival in amyotrophic lateral sclerosis (ALS) patients with mild or moderate disease severity at baseline (S33.003). Neurology. 100, 3698.
    Ludolph, AC., Grandjean, H., Reviers, E., De Micheli, V., Bianchi, C., Cardosi, L., Russ, H., Silani, V. 2023. The preferences of people with amyotrophic lateral sclerosis on riluzole treatment in Europe. Sci. Rep. 13, 1-9.
    Lunn, JS., Sakowski, SA., Hur, J., Feldman, EL. 2011. Stem cell technology for neurodegenerative diseases. Ann. Neurol. 70, 353.
    Maguire, G. 2017. Amyotrophic lateral sclerosis as a protein level, non-genomic disease: Therapy with S2RM exosome released molecules. World J. Stem Cells. 9, 187.
    Majounie, E., Renton, AE., Mok, K., Dopper, EGP., Waite, A., Rollinson, S., Chio, A., Restagno, G., Nicolaou, N., Simon-Sanchez, J., et al., 2012. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: A cross-sectional study. Lancet Neurol. 11, 323-330.
    Mandrioli, J., Malerba, SA., Beghi, E., Fini, N., Fasano, A., Zucchi, E., Pasqua, S De, Guidi, C., Terlizzi, E., Sette, E., et al., 2018. Riluzole and other prognostic factors in ALS: a population-based registry study in Italy. J. Neurol. 265, 817-827.
    Mariani, D., Setti, A., Castagnetti, F., Vitiello, E., Stufera Mecarelli, L., Di Timoteo, G., Giuliani, A., D’Angelo, A., Santini, T., Perego, E., et al., 2024. ALS-associated FUS mutation reshapes the RNA and protein composition of stress granules. Nucleic Acids Res. 52, 13269-13289.
    Martin, D., Thompson, MA., Nadler, JV. 1993. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur. J. Pharmacol. 250, 473-476.
    Martinez-Muriana, A., Mancuso, R., Francos-Quijorna, I., Olmos-Alonso, A., Osta, R., Perry VH., Navarro, X., Gomez-Nicola, D., Lopez-Vales, R. 2016. CSF1R blockade slows the progression of amyotrophic lateral sclerosis by reducing microgliosis and invasion of macrophages into peripheral nerves. Sci. Rep. 6, 25663.
    Mazzini, L., Ferrari, D., Andjus, PR., Buzanska, L., Cantello, R., De Marchi, F., Gelati, M., Giniatullin, R., Glover, JC., Grilli, M., et al., 2018. Advances in stem cell therapy for amyotrophic lateral sclerosis. Expert Opin. Biol. Ther. 18, 865-881.
    McCampbell, A., Cole, T., Wegener, AJ., Tomassy, GS., Setnicka, A., Farley, BJ., Schoch, KM., Hoye, ML., Shabsovich, M., Sun, L., et al., 2018. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J. Clin. Investig. 128, 3558-3567.
    McEachin, ZT., Chung, M., Stratton, SA., Han, C., Kim, WJ., Sheth, U., Thomas E, V., Issenberg, E., Kamra, T., Merino, P., et al., 2025. Molecular impact of antisense oligonucleotide therapy in C9orf72-associated ALS. Cell 188, 6424-6435.
    McMackin, R., Bede, P., Ingre, C., Malaspina, A., Hardiman, O. 2023. Biomarkers in amyotrophic lateral sclerosis: current status and future prospects. Nat. Rev. Neurol. 19, 754-768.
    Mehta, AR., Walters, R., Waldron, FM., Pal, S., Selvaraj, BT., Macleod, MR., Hardingham, GE., Chandran, S., Gregory, JM. 2019. Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis. Brain Commun. 1, fcz009.
    Meininger, V., Lacomblez, L., Salachas F. 2000. What has changed with riluzole? J. Neurol. Supplement. 247, 19-22.
    Merit, C., Bob, D, Nathan, S., Jeremy, S., Jinsy, A., Jonathan, K., James, B., Margaret, O., Catherine, D.., Jenny L., et al., 2025. Design of a Phase 3B trial of debamestrocel in ALS- MDA clinical & scientific conference 2026, in: Dallas, Texas. https://www.mdaconference.org/abstract-library/design-of-a-phase-3b-trial-of-debamestrocel-in-als/ (accessed January 14, 2026)
    Metzger, SL., Littlejohn, KT., Silva, AB., Moses, DA., Seaton, MP., Wang, R., Dougherty, ME., Liu, JR., Wu, P., Berger, MA., et al., 2023. A high-performance neuroprosthesis for speech decoding and avatar control. Nature 620, 1037.
    Meyer, K., Ferraiuolo, L., Miranda CJ., Likhite, S., McElroy, S., Renusch, S., Ditsworth, D., Lagier-Tourenne, C., Smith, RA., Ravits, J., et al., 2014. Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proc. Natl. Acad. Sci. U. S. A. 111, 829-832.
    Miller, RG., Block, G., Katz, JS., Barohn, RJ., Gopalakrishnan, V., Cudkowicz, M., Zhang, JR., McGrath, MS., Ludington, E., Appel, SH., Azhir, A. 2015. Randomized phase 2 trial of NP001-a novel immune regulator: safety and early efficacy in ALS. Neurol. Neuroimmunol. Neuroinflamm. 2, e100.
    Miller, RG., Mitchell, JD., Moore, DH. 2012. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 2012, CD001447.
    Miller, RG., Zhang, R., Block, G., Katz, J., Barohn, R., Kasarskis, E., Forshew, D., Gopalakrishnan, V., Mcgrath, MS. 2014. NP001 regulation of macrophage activation markers in ALS: A phase I clinical and biomarker study. Amyotroph. Lateral Scler. Frontotemporal Degener. 15, 601-609.
    Miller, RG., Zhang, R., Bracci, PM., Azhir, A., Barohn, R., Bedlack, R., Benatar, M., Berry, JD., Cudkowicz, M., Kasarskis, EJ., et al., 2022. Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre-specified and post hoc analyses. Muscle Nerve 66, 39.
    Miller, SL., Green, KM., Crone, B., Switzenberg, JA., Tank, EMH., Krans, A., Jansen-West, K., Wieland, CM., Ji, EW., Petrucelli, L., et al., 2025. Cryptic intronic transcriptional initiation generates efficient endogenous mRNA templates for C9orf72-associated RAN translation. Proc. Natl. Acad. Sci. U. S. A. 122, e2507334122.
    Miller, T., Cudkowicz, M., Shaw, PJ., Andersen, PM., Atassi, N., Bucelli, RC., Genge, A., Glass, J., Ladha, S., Ludolph, AL., et al., 2020. Phase 1-2 trial of antisense oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 383, 109-119.
    Miller, TM., Cudkowicz, ME., Genge, A., Shaw, PJ., Sobue, G., Bucelli, RC., Chio, A., Damme, P Van., Ludolph, AC., Glass, JD., et al., 2022. Trial of antisense oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 387, 1099-1110.
    Miller, TM., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, SH., Andres, PL., Mahoney, K., Allred, P., Alexander, K., et al., 2013. A phase, I., randomised, first-in-human study of an antisense oligonucleotide directed against SOD1 delivered intrathecally in SOD1-familial ALS patients. Lancet Neurol. 12, 435.
    Mitchell JD., O’Brien MR., Joshi M. 2006. Audit of outcomes in motor neuron disease (MND) patients treated with riluzole. Amyotrophic Lateral Sclerosis. 7, 67-71.
    Mitra, J., Guerrero, EN., Hegde, PM., Liachko, NF., Wang, H., Vasquez, V., Gao, J., Pandey, A., Paul Taylor, J., Kraemer, BC., et al., 2019. Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects. Proc. Natl. Acad. Sci. U. S. A. 116, 4696-4705.
    Mitsubishi Tanabe. 2024. Individual Co. Statements - Mitsubishi Tanabe Pharma America. https://us.tanabe-pharma.com/news-and-media/press-releases/2024/mitsubishi-tanabe-pharma-america-inc-mtpa-statement-on-ferrers-phase-3-adore-clinical-trial-of-fnp122-fab122 (accessed December 16, 2025)
    Mizoule, J., Meldrum, B., Mazadier, M., Croucher, M., Ollat, C., Uzan, A., Legrand, J-J., Gueremy, C., Fur, G Le. 1985. 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--I. anticonvulsant properties. Neuropharmacology 24, 767-773.
    Moens, TG., Da Cruz, S., Neumann, M., Shelkovnikova, TA., Shneider, NA., Van Den Bosch L. 2025. Amyotrophic lateral sclerosis caused by FUS mutations: advances with broad implications. Lancet Neurol. 24, 166-178.
    Mora, JS., Bradley, WG., Chaverri, D., Hernandez-Barral, M., Mascias, J., Gamez, J., Gargiulo-Monachelli, GM., Moussy, A., Mansfield, CD., Hermine, O., Ludolph, AC. 2021. Long-term survival analysis of masitinib in amyotrophic lateral sclerosis. Ther. Adv. Neurol. Disord. 14, 17562864211030364.
    Mora, JS., Genge, A., Chio, A., Estol, CJ., Chaverri, D., Hernandez, M., Marin, S., Mascias, J., Rodriguez, GE., Povedano, M., et al., 2020. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph. Lateral Scler. Frontotemporal Degener. 21, 5-14.
    Morata-Tarifa, C., Azkona, G., Glass, J., Mazzini, L., Sanchez-Pernaute R. 2021. Looking backward to move forward: a meta-analysis of stem cell therapy in amyotrophic lateral sclerosis. NPJ Regen. Med. 6, 20.
    Muntoni, F., Wood, MJA. 2011. Targeting RNA to treat neuromuscular disease. Nat. Rev. Drug Discov. 10, 621-637.
    N. Tashiro KTHMYKH& KJY. 1997. Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo-controlled study in Japan. Igakuno Ayumi. 182.
    Nam, JY., Chun, S., Lee, TY., Seo, Y., Kim, K., Park, J., Sung, W., Oh, KW., Lee, S., Park, JS., et al., 2023. Long-term survival benefits of intrathecal autologous bone marrow-derived mesenchymal stem cells (Neuronata-R®: lenzumestrocel) treatment in ALS: Propensity-score-matched control, surveillance study. Front. Aging Neurosci. 15, 1148444.
    Nam, JY., Lee, TY., Kim, K., Chun, S., Kim, MS., Shin, JH., Sung, JJ., Kim, BJ., Kim, BJ., Oh, KW., et al., 2022. Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial. Trials 23, 415.
    Neumann, M., Sampathu, DM., Kwong, LK., Truax, AC., Micsenyi, MC., Chou, TT., Bruce, J., Schuck, T., Grossman, M., Clark, CM., et al., 2006. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-133.
    Neuvivo. 2025. Mounting Evidence Demonstrates Neuvivo’s NP001 Spares Lung Function and Substantially Extends Survival in ALS Patients. https://www.businesswire.com/news/home/20250123661115/en/Mounting-Evidence-Demonstrates-Neuvivos-NP001-Spares-Lung-Function-and-Substantially-Extends-Survival-in-ALS-Patients (accessed December 22, 2025)
    Nicaise, C., Mitrecic, D., Falnikar, A., Lepore, AC. 2015. Transplantation of stem cell-derived astrocytes for the treatment of amyotrophic lateral sclerosis and spinal cord injury. World J. Stem Cells. 7, 380.
    Nicolas, A., Kenna, K., Renton, AE., Ticozzi, N., Faghri, F., Chia, R., Dominov, JA., Kenna, BJ., Nalls, MA., Keagle, P., et al., 2018. Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron 97, 1268-1283.
    Nijs, M., Van Damme P. 2024. The genetics of amyotrophic lateral sclerosis. Curr. Opin. Neurol. 37, 560.
    Latimer, N., Abrams, K. 2014. NICE DSU Technical Support Document 16: Adjusting Survival Time Estimates in the Presence of Treatment Switching [Internet]. https://pubmed.ncbi.nlm.nih.gov/27466662/
    O’Brien, J., Hayder, H., Zayed, Y., Peng C. 2018. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front. Endocrinol. 9, 402.
    Oh, K-W., Moon, C., Kim, HY., Oh, S., Park, J., Lee, JH., Chang, IY., Kim, KS., Kim, SH. 2015. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Stem Cells Transl. Med. 4, 590-597.
    Oh, KW., Noh, MY., Kwon, MS., Kim, HY., il Oh, S., Park, J., Kim, HJ., Ki, CS., Kim, SH. 2018. Repeated intrathecal mesenchymal stem cells for amyotrophic lateral sclerosis. Ann. Neurol. 84, 361.
    Orsini, M., Oliveira, AB., Nascimento, OJM., Reis, CHM., Leite, MAA., de Souza, JA., Pupe, C., de Souza, OG., Bastos, VH., de Freitas, MRG., et al., 2015. Amyotrophic lateral sclerosis: new perspectives and update. Neurol. Int. 7, 5885.
    Otomo, E., Tohgi, H., Kogure, K., Hirai, S., Takakura, K., Terashi, A., Gotoh, F., Maruyama, S., Tazaki, Y., Shinohara, Y., et al., 2003. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction: randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc. Dis. 15, 222-229.
    Paganoni, S., Hendrix, S., Dickson, SP., Knowlton, N., Macklin, EA., Berry, JD., Elliott, MA., Maiser, S., Karam, C., Caress, JB., et al., 2020. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve 63, 31.
    Paganoni, S., Macklin, EA., Hendrix, S., Berry, JD., Elliott, MA., Maiser, S., Karam, C., Caress, JB., Owegi, MA., Quick, A., et al., 2020. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N. Engl. J. Med. 383, 919-930.
    Paganoni, S., Watkins, C., Cawson, M., Hendrix, S., Dickson, SP., Knowlton, N., Timmons, J., Manuel, M., Cudkowicz M. 2022. Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes. Muscle Nerve 66, 136.
    Papadeas, ST., Kraig, SE., O’Banion, C., Lepore, AC., Maragakis, NJ. 2011. Astrocytes carrying the superoxide dismutase 1 (SOD1 G93A) mutation induce wild-type motor neuron degeneration in vivo. Proc. Natl. Acad. Sci. U. S. A. 108, 17803-17808.
    Petrou, P., Gothelf, Y., Argov, Z., Gotkine, M., Levy, YS., Kassis, I., Vaknin-Dembinsky, A., Ben-Hur, T., Offen, D., Abramsky, O., et al., 2016. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials. JAMA Neurol. 73, 337-344.
    Poesen, K., De Schaepdryver, M., Stubendorff, B., Gille, B., Muckova, P., Wendler, S., Prell, T., Ringer, TM., Rhode, H., Stevens, O., et al., 2017. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurol. 88, 2302-2309.
    Rajagopalan, V., Pioro, EP. 2022. Graph theory network analysis provides brain MRI evidence of a partial continuum of neurodegeneration in patients with UMN-predominant ALS and ALS-FTD. Neuroimage Clin. 35, 103037.
    Ratti, A., Gumina, V., Lenzi, P., Bossolasco, P., Fulceri, F., Volpe, C., Bardelli, D., Pregnolato, F., Maraschi, AM., Fornai, F., et al., 2020. Chronic stress induces formation of stress granules and pathological TDP-43 aggregates in human ALS fibroblasts and iPSC-motoneurons. Neurobiol. Dis. 145, 105051.
    Renton, AE., Majounie, E., Waite, A., Simon-Sanchez, J., Rollinson, S., Gibbs, JR., Schymick, JC., Laaksovirta, H., van Swieten, JC., Myllykangas, L., et al., 2011. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257-268.
    Rinaldi, C., Wood MJA. 2018. Antisense oligonucleotides: The next frontier for treatment of neurological disorders. Nat. Rev. Neurol. 14, 9-22.
    Roberts, K., Zeineddine, R., Corcoran, L., Li, W., Campbell, IL., Yerbury, JJ. 2013. Extracellular aggregated Cu/Zn superoxide dismutase activates microglia to give a cytotoxic phenotype. Glia. 61, 409-419.
    Rodrigues, CMP., Sola, S., Sharpe JC., Moura JJG., Steer CJ. 2003. Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome C release in isolated mitochondria. Biochemistry 42, 3070-3080.
    Rosen, DR., Siddique, T., Patterson, D., Figlewicz, DA., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O’Regan, JP., Deng, HX., et al., 1993. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62.
    Rothstein, JD., Dykes-Hoberg, M., Pardo, CA., Bristol, LA., Jin, L., Kuncl, RW., Kanai, Y., Hediger, MA., Wang, Y., Schielke, JP., Welty, DF. 1996. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16, 675-686.
    Rowland, LP. 1994. Riluzole for the treatment of amyotrophic lateral sclerosis - too soon to tell. N. Engl. J. Med. 330, 636-637.
    Satija, NK., Singh, VK., Verma, YK., Gupta, P., Sharma, S., Afrin, F., Sharma, M., Sharma, P., Tripathi, RP., Gurudutta, GU. 2009. Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine. J. Cell. Mol. Med. 13, 4385.
    Sharma, A., Lyashchenko, AK., Lu, L., Nasrabady, SE., Elmaleh, M., Mendelsohn, M., Nemes, A., Tapia, JC., Mentis, GZ., Shneider, NA. 2016. ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Nat. Commun. 7, 10465.
    Shefner, J., Heiman-Patterson, T., Pioro EP., Wiedau-Pazos, M., Liu, S., Zhang, J., Agnese, W., Apple, S. 2019. Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19). Muscle Nerve 61, 218.
    Shneider, NA., Harms, MB., Korobeynikov, VA., Rifai, OM., Hoover, BN., Harrington, EA., Aziz-Zaman, S., Singleton, J., Jamil, A., Madan, VR., et al., 2025. Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series. Lancet 405, 2075-2086.
    Signore, SJ Del, Amante, DJ., Kim, J., Stack, EC., Goodrich, S., Cormier, K., Smith, K., Cudkowicz, ME., Ferrante, RJ. 2009. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph. Lateral Scler. 10, 85-94.
    Smith, RA., Miller, TM., Yamanaka, K., Monia, BP., Condon, TP., Hung, G., Lobsiger, CS., Ward, CM., McAlonis-Downes, M., Wei, H., et al., 2006. Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. 116, 2290.
    Song, J-H., Huang, C-S., Nagata, K., Yeh, JZ., Narahashi, T. 1997. Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels1. J. Pharmacol. Exp. Ther. 282, 707-714.
    Stephenson, ML., Zamecnik, PC. 1978. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. U. S. A. 75, 285-288.
    Stevic, Z., Kostic-Dedic, S., Peric, S., Dedic, V., Basta, I., Rakocevic-Stojanovic, V., Lavrnic D. 2016. Prognostic factors and survival of ALS patients from Belgrade, Serbia. Amyotroph. Lateral Scler. Frontotemporal Degener. 17, 508-514.
    Straczkiewicz, M., Karas, M., Johnson, SA., Burke, KM., Scheier, Z., Royse, TB., Calcagno, N., Clark, A., Iyer, A., Berry, JD., Onnela, JP. 2024. Upper limb movements as digital biomarkers in people with ALS. EBioMedicine 101, 105036.
    Suk, TR., Rousseaux, MWC. 2020. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol. Neurodegener. 15, 1-16.
    Swarup, V., Phaneuf, D., Bareil, C., Robertson, J., Rouleau, GA., Kriz, J., Julien, JP. 2011. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain 134, 2610-2626.
    Swinnen, B., Robberecht W. 2014. The phenotypic variability of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 10, 661-670.
    Tahedl, M., Murad, A., Lope, J., Hardiman, O., Bede, P. 2021. Evaluation and categorisation of individual patients based on white matter profiles: Single-patient diffusion data interpretation in neurodegeneration. J. Neurol. Sci. 428, 117584.
    Terry, H., Johnna, P., Wendy, A., Stephen, A. 2025. Real-world evidence of Radicava® (edaravone) for amyotrophic lateral sclerosis from a national infusion center database in the United States-MDA Clinical & Scientific Conference 2026. https://www.mdaconference.org/abstract-library/real-world-evidence-of-radicava-edaravone-for-amyotrophic-lateral-sclerosis-from-a-national-infusion-center-database-in-the-united-states/ (accessed January 14, 2026)
    Thonhoff, JR., Beers, DR., Zhao, W., Faridar, A., Thome, A., Wen, S., Zhang, A., Wang, J., Appel, SH. 2024. A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic lateral sclerosis. Front. Neurol. 15, 1415106.
    Di Timoteo, G., Giuliani, A., Setti, A., Biagi, MC., Lisi, M., Santini, T., Grandioso, A., Mariani, D., Castagnetti, F., Perego, E., et al., 2024. M6A reduction relieves FUS-associated ALS granules. Nat. Commun. 15, 5033.
    Traynor, BJ., Alexander, M., Corr, B., Frost, E., Hardiman, O. 2003. An outcome study of riluzole in amyotrophic lateral sclerosis: A population-based study in Ireland, 1996-2000. J. Neurol. 250, 473-479.
    Trias, E., Ibarburu, S., Barreto-Nunez, R., Babdor, J., Maciel, TT., Guillo, M., Gros, L., Dubreuil, P., Diaz-Amarilla, P., Cassina, P., et al., 2016. Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J. Neuroinflammation. 13, 1-12.
    Trias, E., King, PH., Si, Y., Kwon, Y., Varela, V., Ibarburu, S., Kovacs, M., Moura, IC., Beckman, JS., Hermine, O., Barbeito, L. 2018. Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS. JCI Insight. 3, e123249.
    Trias, E., Kovacs, M., King, PH., Si, Y., Kwon, Y., Varela, V., Ibarburu, S., Moura, IC., Hermine, O., Beckman, JS., Barbeito, L. 2019. Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL-34 and SCF in amyotrophic lateral sclerosis. Glia. 68, 1165.
    Tsang, CK wan, Liu, Y., Thomas, J., Zhang, Y., Zheng, XFS. 2014. Superoxide dismutase 1 acts as a nuclear transcription factor to regulate oxidative stress resistance. Nat. Commun. 5, 3446.
    Turner, MR., Bakker, M., Sham, P., Shaw, CE., Leigh, PN., Al-Chalabi, A. 2002. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 3, 15-21.
    uniQure. 2025a. ALS (SOD1) | Programs & Pipeline | uniQure. https://www.uniqure.com/programs-pipeline/als-sod1 (accessed January 14, 2026)
    uniQure. 2025b. uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS | uniqure BV. https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-favorable-recommendation-independent-data (accessed January 14, 2026)
    Vance, C., Rogelj, B., Hortobagyi, T., Vos, KJ De, Nishimura, AL., Sreedharan, J., Hu, X., Smith, B., Ruddy, D., Wright, P., et al., 2009. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208-1211.
    Vansteensel, MJ., Leinders, S., Branco, MP., Crone, NE., Denison, T., Freudenburg, ZV., Geukes, SH., Gosselaar, PH., Raemaekers, M., Schippers, A., et al., 2024. Longevity of a brain-computer interface for amyotrophic lateral sclerosis. N. Engl. J. Med. 391, 619-626.
    Vasta, R., Ombelet, F., Hobin, F., Manera, U., Ammar, AC., Puchades, AC., Corcia, P., Galvin, M., Hardiman, O., Heverin, M., et al., 2025. Real-world prognostic role of riluzole use in ALS: a multi-center study from PRECISION-ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 26, 50-60.
    Verde, F., Milone, I., Maranzano, A., Colombo, E., Torre, S., Solca, F., Doretti, A., Gentile, F., Manini, A., Bonetti, R., et al., 2023. Serum levels of glial fibrillary acidic protein in patients with amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 10, 118-129.
    Vieira de Sa, R., Sudria-Lopez, E., Canizares Luna, M., Harschnitz, O., van den Heuvel, DMA., Kling, S., Vonk, D., Westeneng, HJ., Karst, H., Bloemenkamp, L., et al., 2024. ATAXIN-2 intermediate-length polyglutamine expansions elicit ALS-associated metabolic and immune phenotypes. Nat. Commun. 15, 7484.
    Vignali, DAA., Collison, LW., Workman, CJ. 2008. How regulatory T cells work. Nat. Rev. Immunol. 8, 523-532.
    Walhout, R., Westeneng, HJ., Verstraete, E., Hendrikse, J., Veldink, JH., Van Den Heuvel, MP., Van Den Berg, LH. 2015. Cortical thickness in ALS: towards a marker for upper motor neuron involvement. J. Neurol. Neurosurg. Psychiatry. 86, 288-294.
    Walker, LSK., Sansom, DM. 2011. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat. Rev. Immunol. 11, 852-863.
    Wang, H., Guan, LP., Deng M. 2023. Recent progress of the genetics of amyotrophic lateral sclerosis and challenges of gene therapy. Front. Neurosci. 17, 1170996.
    Wang, L., Gutmann, DH., Roos, RP. 2011. Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Hum. Mol. Genet. 20, 286-293.
    Watanabe, K., Tanaka, M., Yuki, S., Hirai, M., Yamamoto, Y. 2018. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? J. Clin. Biochem. Nutr. 62, 20-38.
    Watanabe, M., Dykes-Hoberg, M., Cizewski Culotta, V., Price, DL., Wong, PC., Rothstein, JD. 2001. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol. Dis. 8, 933-941.
    Webster, CP., Smith, EF., Bauer, CS., Moller, A., Hautbergue, GM., Ferraiuolo, L., Myszczynska MA., Higginbottom, A., Walsh MJ., Whitworth AJ., et al., 2016. The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy. EMBO J. 35, 1656-1676.
    Wen, J., Zhang, H., Alexander, DC., Durrleman, S., Routier, A., Rinaldi, D., Houot, M., Couratier, P., Hannequin, D., Pasquier, F., et al., 2019. Neurite density is reduced in the presymptomatic phase of C9orf72 disease. J. Neurol. Neurosurg. Psychiatry 90, 387-394.
    Wiesenfarth, M., Dorst, J., Brenner, D., Elmas, Z., Parlak O, Uzelac, Z., Kandler, K., Mayer, K., Weiland, U., Herrmann, C., et al., 2024. Effects of tofersen treatment in patients with SOD1-ALS in a “real-world” setting-a 12-month multicenter cohort study from the German early access program. EClinicalMedicine 69, 102495.
    Wiley, JC., Pettan-Brewer, C., Ladiges, WC. 2011. Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice. Aging Cell 10, 418-428.
    Willett, FR., Kunz, EM., Fan, C., Avansino, DT., Wilson, GH., Choi, EY., Kamdar, F., Glasser, MF., Hochberg, LR., Druckmann, S., et al., 2023. A high-performance speech neuroprosthesis. Nature 620, 1031.
    Witzel, S., Maier, A., Steinbach, R., Grosskreutz, J., Koch, JC., Sarikidi, A., Petri, S., Gunther, R., Wolf, J., Hermann, A., et al., 2022. Safety and efectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 79, 1.
    Wu, H., Lima WF., Zhang, H., Fan, A., Sun, H., Crooke, ST. 2004. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem. 279, 17181-17189.
    Xu, J., Su, X., Burley, SK., Zheng, XFS. 2022. Nuclear SOD1 in growth control, oxidative stress response, amyotrophic lateral sclerosis, and cancer. Antioxidants 11, 427.
    Xu, L., Liu, T., Liu, L., Yao, X., Chen, L., Fan, D., Zhan, S., Wang S. 2020. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J. Neurol. 267, 944-953.
    Yoshino, H., Kimura, A. 2006. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study). Amyotroph. Lateral Scler. 7, 247-251.
    Zhang, K., Daigle, JG., Cunningham, KM., Coyne, AN., Ruan, K., Grima, JC., Bowen, KE., Wadhwa, H., Yang, P., Rigo, F., et al., 2018. Stress granule assembly disrupts nucleocytoplasmic transport. Cell 173, 958.
    Zhou, L., Xie, M., Wang, X., Xu, R. 2024. The usage and advantages of several common amyotrophic lateral sclerosis animal models. Front. Neurosci. 18, 1341109.
    Zoccolella, S., Beghi, E., Palagano, G., Fraddosio, A., Guerra, V., Samarelli, V., Lepore, V., Simone, IL., Lamberti, P., Serlenga, L., Logroscino, G. 2007. Riluzole and amyotrophic lateral sclerosis survival: A population-based study in southern Italy. Eur. J. Neurol. 14, 262-268.
    Zou, ZY., Zhou, ZR., Che, CH., Liu, CY., He, RL., Huang, HP. 2017. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 88, 540-549.
    Zuo, X., Zhou, J., Li, Y., Wu, K., Chen, Z., Luo, Z., Zhang, X., Liang, Y., Esteban, MA., Zhou, Y., Fu, XD. 2021. TDP-43 aggregation induced by oxidative stress causes global mitochondrial imbalance in ALS. Nat. Struct. Mol. Biol. 28, 132-142.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF

    Article Metrics

    Article views (10) PDF downloads (0) Cited by ()
    Proportional views
    Related

    Editorial Office

    Journal of Genetics and Genomics

    京ICP备09063187号-12

    No.1, West Beichen Road, Chaoyang District, Beijing 100101, P.R.China

    +86-10-64806528+86-10-64807786jgg@genetics.ac.cn

    Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return